Clinical Trial Search

Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005

Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38

Primary: True Allergy (Consistent With an IgE-mediated Reaction) — 135 Allergies

Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts

Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale

Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer

Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm

Primary: Combined Rhinoconjunctivitis Symptom and Medication Score — 0.86; 0.64; 0.72 score (maximum=3)

Primary: Change in Health-related Quality of Life Score From Baseline to the Peak Week of Allergy Season for Probiotic Versus Placebo, as Measured by MiniRQLQ — -0.1946; -0.6772…

Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants

Primary: Desensitisation — 7; 5; 2 Participants

Primary: Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy — 6; 4; 3 participants

Primary: Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation. — 0.69; 2.27 units on a scale

Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units

Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…

Primary: Wheal Response — 6.8 mm

Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg

Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants

Primary: Average of the Combined Rhinoconjunctivitis Symptom and Medication Score (RSMS) Obtained Daily During the Birch Pollen Season — 0.853; 0.795; 0.959 units on a scale

Primary: D. Farinae Specific IgG4 Change From Baseline to End of Treatment — 0.473; -0.01 mg antibody/ml

Primary: Change in Basophil Surface IgE — -95; -10 percentage of basophil surface IgE

Primary: Percent of Participants Who Successfully Consumed 10,000 mg of Egg White Solid Followed by Open Feeding of Egg — 27.5; 0 percentage of participants — p=0.025

Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants

Primary: Percentage of Subjects Achieving Tolerance as Defined by a Negative DBPCFC 4 Weeks After Discontinuation of Peanut OIT Therapy. — 89 percentage of participants

Primary: Comparison of Th2 Cytokines (IL-13) Between Placebo and Probiotic Groups at Baseline (Beginning of Product Intake), 4 Weeks (Mid Period of Product Intake) and 8 Weeks…

Primary: Total Nasal Cell Count in Response to DEP Challenge at 0, 6 and 24 hr With or Without BSE Intervention — 4.44; 4.50; 4.73; 4.70 log cells/mL — p=<0.001

Primary: Percentage of Subjects in the Xolair® (Omalizumab) Group vs. Placebo Group Developing Clinical Tolerance to Milk — 46.4; 34.5 Percent of participants — p=0.42

Primary: Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT) — 32; 17; 49 participants

Primary: Tolerance or Sustained Unresponsiveness — 2; 7 Participants

Primary: Area Under the Curve [AUC](Total Score of Symptoms Taking Into Account the Total 5 Symptom Score (T5SS) and Consumption of Rescue Medications (RM) on the Y-axis, and…